Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04900818 · ClinicalTrials.gov registry record · Phase 1
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
A Phase 1 study of Solid Tumor and Gastric Cancer, sponsored by I-Mab Biopharma US Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 330
- Enrollment target
- 20
- Study locations
NCT04900818 is a Phase 1 study of Solid Tumor and Gastric Cancer that is actively recruiting participants, run by I-Mab Biopharma US Limited. The registered enrollment target is 330 participants, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (50% higher). The trial reports 20 study locations across 19 states.
The verdict
NCT04900818, a Phase 1 study of Solid Tumor and Gastric Cancer, is actively recruiting participants, sponsored by I-Mab Biopharma US Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 330 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.
Conditions Studied
Interventions
- DRUG TJ033721 (givastomig)
- DRUG TJ033721 (givastomig) , nivolumab, chemotherapy
- DRUG TJ033721 (givastomig), chemotherapy
- DRUG TJ033721 (givastomig), durvalumab, chemotherapy
Study Locations (20)
New York
- NYU Langone - New York
- Memorial Sloan Kettering Cancer Center - New York
California
- Stern Center for Cancer Clinical Trials and Research - Orange
Colorado
- UCHealth Cancer Care - Anschutz Medical Campus - Aurora
Indiana
- Horizon Oncology Research, LLC. - Layfayette
Massachusetts
- Mass General Hospital - Boston
New Jersey
- Rutgers Cancer Institute of New Jersey - New Brunswick
North Carolina
- Carolina BioOncology Institute - Huntersville
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2021-06-29 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04900818
The ClinicalTrials.gov registry entry for NCT04900818 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 330 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 220-participant average among 196 other Solid Tumor trials with a reported enrollment target (50% higher). The listed sponsor is I-Mab Biopharma US Limited, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Solid Tumor appearing as the primary indexed condition, and to 4 interventions - of which TJ033721 (givastomig) is the first listed.
NCT04900818 reports 20 study locations spanning 19 distinct geographic areas - top geographies include New York, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT04900818 about?
NCT04900818 is a clinical study titled "Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors". This is an open label, multi-center, multiple dose Phase 1 study to evaluate the safety, tolerability, MTD PK, and PD of TJ033721 (givastomig) in subjects with advanced or metastatic solid tumors.
What is the current status of trial NCT04900818?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 330 participants. The study started on 2021-06-29. Estimated completion is 2027-12.
What conditions does trial NCT04900818 study?
This clinical trial studies the following conditions: Solid Tumor, Gastric Cancer, Advanced Cancer, Metastatic Cancer, Esophageal Adenocarcinoma.
What interventions are being tested in trial NCT04900818?
The interventions under investigation include: TJ033721 (givastomig) (DRUG), TJ033721 (givastomig) , nivolumab, chemotherapy (DRUG), TJ033721 (givastomig), chemotherapy (DRUG), TJ033721 (givastomig), durvalumab, chemotherapy (DRUG).
Who is sponsoring clinical trial NCT04900818?
This trial is sponsored by I-Mab Biopharma US Limited, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04900818 being conducted?
This trial has 20 study locations across California, Colorado, Indiana, Massachusetts, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.